Duvelisib plus venetoclax was shown to be active in R/R CLL and Richter syndrome, including in patients with high-risk, TP53-aberrant disease and those who had previously received BTK inhibitors.
@ASH_hematology @JenCrombieMD @DanaFarberNews #ASH24 #leusm